← Leaderboards

Dean E. Brenner

University Of Michigan At Ann Arbor

Google Scholar ↗PubMed ↗ORCID ↗

$31,108,993

Attributed

$37,450,818

Total exposure

16

Grants

8

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY2005–23

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

Funding mix

By agency

NIH$49,279,165 · 17

By mechanism

U01$21,134,662 · 1

P50$16,894,352 · 3

UG1$5,637,006 · 1

UH3$2,424,222 · 1

U10$2,361,021 · 1

UG3$714,821 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Bruce G Redman$679,712

Others in their field

Top investigators on “Malignant Neoplasms”

David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Richard K. Wilson · Washington University$274,272,747
Larry Arthur$223,443,122
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879

Research focus

Malignant NeoplasmsUniversitiesResourcesValidationResponseDesignSamplingBiological MarkersEarly DiagnosisBaseResearch PersonnelHuman SubjectSerumColorectal AdenocarcinomaLinkFundingProgramsColorectal CancerEarly Detection Research NetworkMichiganCancer PreventionNeoplasmsTranslational ResearchScience

Grant awards (72)

Early Phase Clinical Cancer Prevention Consortium$1,538,896

UG1 · FY2023 · CA · contact PI

Early Phase Clinical Cancer Prevention Consortium$1,564,126

UG1 · FY2022 · CA · contact PI

Rapid Point of Care Detection of HPV-Associated Malignancies$821,873

UH3 · FY2022 · CA

Early Phase Clinical Cancer Prevention Consortium$1,569,332

UG1 · FY2021 · CA · contact PI

Rapid Point of Care Detection of HPV-Associated Malignancies$823,353

UH3 · FY2021 · CA

Great Lakes New England Clinical Validation Center$627,186

U01 · FY2021 · CA · contact PI

Early Phase Clinical Cancer Prevention Consortium$964,652

UG1 · FY2020 · CA · contact PI

Great Lakes New England Clinical Validation Center$752,098

U01 · FY2020 · CA · contact PI

Rapid Point of Care Detection of HPV-Associated Malignancies$1

UH3 · FY2020 · CA

Rapid Point of Care Detection of HPV-Associated Malignancies$778,995

UH3 · FY2019 · CA

Great Lakes New England Clinical Validation Center$272,820

U01 · FY2019 · CA · contact PI

Great Lakes New England Clinical Validation Center$1,178,448

U01 · FY2018 · CA · contact PI

Rapid Point of Care Detection of HPV-Associated Malignancies$338,933

UG3 · FY2018 · CA

Great Lakes New England Clinical Validation Center$1,315,798

U01 · FY2017 · CA · contact PI

Rapid Point of Care Detection of HPV-Associated Malignancies$375,888

UG3 · FY2017 · CA

Great Lakes New England Clinical Validation Center$1,374,531

U01 · FY2016 · CA · contact PI

Translational Research in GI Cancer$1,100,000

P50 · FY2016 · CA · contact PI

Great Lakes/New England Clinical Validation Center$136,008

U01 · FY2015 · CA · contact PI

Translational Research in GI Cancer$1,899,055

P50 · FY2014 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$893,380

P50 · FY2014 · CA · contact PI

Great Lakes/New England Clinical Validation Center$636,850

U01 · FY2014 · CA · contact PI

Administrative Core$180,611

P50 · FY2014 · CA · contact PI

Translational Research in GI Cancer$27,687

P50 · FY2014 · CA · contact PI

Translational Research in GI Cancer$2,051,220

P50 · FY2013 · CA · contact PI

Great Lakes/New England Clinical Validation Center$633,530

U01 · FY2013 · CA · contact PI

Administrative Core$296,437

P50 · FY2013 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$250,146

P50 · FY2013 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$163,133

P50 · FY2013 · CA · contact PI

Translational Research in GI Cancer$163,133

P50 · FY2013 · CA · contact PI

Translational Research in GI Cancer$2,193,817

P50 · FY2012 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$861,341

P50 · FY2012 · CA · contact PI

Great Lakes/New England Clinical Validation Center$691,268

U01 · FY2012 · CA · contact PI

Administrative Core$246,476

P50 · FY2012 · CA · contact PI

Great Lakes/New England Clinical Validation Center$109,792

U01 · FY2012 · CA · contact PI

Translational Research in GI Cancer$57,746

P50 · FY2012 · CA · contact PI

Translational Research in GI Cancer$2,084,126

P50 · FY2011 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$827,153

P50 · FY2011 · CA · contact PI

Great Lakes/New England Clinical Validation Center$705,379

U01 · FY2011 · CA · contact PI

Administrative Core$221,697

P50 · FY2011 · CA · contact PI

Translational Research in GI Cancer$57,746

P50 · FY2011 · CA · contact PI

Translating Cancer Prevention Research in the Developing World$25,000

R13 · FY2011 · CA · contact PI

Translational Research in GI Cancer$2,193,817

P50 · FY2010 · CA · contact PI

P1 - Omega-3 fatty acids and Colorectal Cancer Prevention$887,448

P50 · FY2010 · CA · contact PI

Great Lakes/New England Clinical Validation Center$796,289

U01 · FY2010 · CA · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$298,416

U01 · FY2010 · CA · contact PI

Administrative Core$238,183

P50 · FY2010 · CA · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$1,173,004

U01 · FY2009 · CA · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$1,145,611

U01 · FY2008 · CA · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$1,091,808

U01 · FY2007 · CA · contact PI

Translational Research in Cancer Prevention$20,000

R13 · FY2007 · CA · contact PI

University of Michigan Comprehensive Cancer Center CCOP*$14,723

U10 · FY2007 · CA · contact PI

CLIN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RESVERATROL$7,005

M01 · FY2007 · RR · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$1,138,264

U01 · FY2006 · CA · contact PI

University of Michigan Comprehensive Cancer Center CCOP*$460,524

U10 · FY2006 · CA · contact PI

Great Lakes/New England Clinical Epidemiology/Validation$1,191,805

U01 · FY2005 · CA

University of Michigan Comprehensive Cancer Center CCOP*$564,251

U10 · FY2005 · CA

GREAT LAKES NEW ENGLAND CLINICAL AND EPIDEMIOLOGY CENTER$1,186,081

U01 · FY2004 · CA

University of Michigan Comprehensive Cancer Center$560,720

U10 · FY2004 · CA

Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation$40,664

M01 · FY2004 · RR

Cancer Prevention: Translation of Molecular Revolution$20,000

R13 · FY2004 · CA

GREAT LAKES NEW ENGLAND CLINICAL AND EPIDEMIOLOGY CENTER$886,256

U01 · FY2003 · CA

UNIVERSITY OF MICHIGAN CCOP RESEARCH BASE$280,128

U10 · FY2003 · CA

GREAT LAKES NEW ENGLAND CLINICAL AND EPIDEMIOLOGY CENTER$1,297,689

U01 · FY2002 · CA

UNIVERSITY OF MICHIGAN CCOP RESEARCH BASE$249,879

U10 · FY2002 · CA

PILOT--BIOMEDICAL PROGRAM$0

P30 · FY2002 · CA

GREAT LAKES NEW ENGLAND CLINICAL AND EPIDEMIOLOGY CENTER$1,388,611

U01 · FY2001 · CA

UNIVERSITY OF MICHIGAN CCOP RESEARCH BASE$230,796

U10 · FY2001 · CA

PILOT--BIOMEDICAL PROGRAM$0

P30 · FY2001 · CA

GREAT LAKES NEW ENGLAND CLINICAL AND EPIDEMIOLOGY CENTER$1,107,120

U01 · FY2000 · CA

CHEMOPREVENTION OF DEFLUOROMETHYLORNITHINE IN INTESTINAL BARRETTS ESOPHAGUS$206

M01 · FY2000 · RR

UMCC 9715--PHARMACOKINETICS OF CURCUMIN ADMINISTERED AS MICRONIZED FORMULATION$206

M01 · FY2000 · RR

PHASE I SINGLE &MULTIPLE-DOSE SAFETY$0

N01 · FY2000 · CN